Recent Finacing
Recent Raise
Chord Therapeutics is a Geneva-based clinical-stage biopharmaceutical company developing oral disease-modifying therapies for rare autoimmune disorders, advancing lead compound CRD1 (cladribine) with FDA orphan designation into Phase 2.
